Drug Trial Radar · NCT02291861
Addressing Involuntary Movements in Tardive Dyskinesia
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
298
Actual
Start
Oct 31, 2014
Primary completion
Aug 19, 2016
Study completion Aug 19, 2016
Sponsor
- Lead sponsor
- Auspex Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
Conditions
- Tardive Dyskinesia
Interventions
SD-809Drug
SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
PlaceboDrug
Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using a Mixed Model For Repeated Measures (MMRM)Time frame: Day 0 (Baseline), Weeks 2, 4, 8 and 12
Locations
106 sites in 6 countries. Site status is shown where the registry gives one.
Teva Investigational Site 145
Tuscaloosa, Alabama
Teva Investigational Site 107
Anaheim, California
Teva Investigational Site 108
Anaheim, California
Teva Investigational Site 123
Glendale, California
Teva Investigational Site 177
Imperial, California
Teva Investigational Site 160
Irvine, California
Teva Investigational Site 106
Irvine, California
Teva Investigational Site 176
Loma Linda, California
Teva Investigational Site 121
Los Angeles, California
Teva Investigational Site 147
Los Angeles, California
Teva Investigational Site 174
Norwalk, California
Teva Investigational Site 170
Oceanside, California
Teva Investigational Site 102
Orange, California
Teva Investigational Site 104
San Bernardino, California
Teva Investigational Site 110
San Diego, California
Teva Investigational Site 169
San Rafael, California
Teva Investigational Site 129
Englewood, Colorado
Teva Investigational Site 139
New Haven, Connecticut
Teva Investigational Site 156
Washington D.C., District of Columbia
Teva Investigational Site 157
Boca Raton, Florida
Teva Investigational Site 117
Gainesville, Florida
Teva Investigational Site 150
Lake City, Florida
Teva Investigational Site 153
Miami, Florida
Teva Investigational Site 162
Miami, Florida
Teva Investigational Site 112
Orlando, Florida
Teva Investigational Site 144
Port Charlotte, Florida
Teva Investigational Site 155
Augusta, Georgia
Teva Investigational Site 165
Decatur, Georgia
Teva Investigational Site 131
Chicago, Illinois
Teva Investigational Site 113
Chicago, Illinois
Teva Investigational Site 164
Kansas City, Kansas
Teva Investigational Site 154
Baltimore, Maryland
Teva Investigational Site 101
Glen Burnie, Maryland
Teva Investigational Site 135
Boston, Massachusetts
Teva Investigational Site 118
Creve Coeur, Missouri
Teva Investigational Site 142
Kansas City, Missouri
Teva Investigational Site 175
St Louis, Missouri
Teva Investigational Site 161
St Louis, Missouri
Teva Investigational Site 178
Lincoln, Nebraska
Teva Investigational Site 128
Albuquerque, New Mexico
Showing 40 of 106 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.